Table 3 Procedure in the personalized psychological treatment arm

1)

Patient is referred for participation in this trial via their treating doctor or via self-referral.

2)

Screening, baseline assessment (T0), and randomization.

3)

Intake interview (verification patients’ most burdensome symptom and patients’ preference for face-to-face, blended, or Internet therapy). Following the standard protocols of the treatment for fear or cancer recurrence, fatigue, or depression, additional questionnaires need to be filled out.

4)

Start of EMA assessment during 14 consecutive days. Auto-VAR analyses to identify the most important maintaining factor on which to intervene first, besides the mandatory modules.

5)

Results of EMA assessment and additional questionnaires are discussed.

6)

Start treatment aimed at maintaining factors for the most burdensome symptom.

7)

Evaluation of treatment response through measurement of symptom level and progression on individual treatment goals. The therapist discusses with the patient whether treatment continuation or treatment conclusion is indicated. If treatment continues, the second EMA assessment determines which treatment modules to add or repeat.

8)

6 months after intake, follow-up assessment (T1); if treatment continues additional assessment at end of treatment.

9)

12 months after intake, follow-up assessment (T2).